A recent study has identified T‐helper cell types‐1, ‐17 and ‐22 (Th1, Th17, and Th22) cells as primary source and CD11b+ cells as a contributing source of IL‐22 in breast cancer TME (Voigt et al., 2017). Here, IL22 is linked to breast carcinoma.